Suggested remit: To appraise the clinical and cost effectiveness of avacopan within its marketing authorisation for treating anti-neutrophil cytoplasmic antibody-associated vasculitis.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
STA 2018
|
| ID number |
1581
|
Provisional Schedule
| Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
24 May 2022 - 17 June 2022 |
| Committee meeting: 2 |
07 July 2022 |
| Expected publication |
07 September 2022 |
Project Team
Email enquiries
Stakeholders
| Companies sponsors |
Vifor Pharma UK (avacopan) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Vasculitis UK |
| Professional groups |
British Association for Paediatric Nephrology |
| |
British Association of Dermatologists |
| |
British Society for Rheumatology |
| |
Royal College of Physicians |
| |
UK Kidney Association |
| |
UK Renal Pharmacy Group |
| Comparator companies |
Novartis (mycophenolate) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
UK and Ireland Vasculitis Rare Disease Group |
|
Date
|
Update
|
|
05 May 2022
|
Committee meeting |
|
25 August 2021
|
Invitation to participate |
|
19 February 2021
|
The Department for Health and Social Care has asked NICE to conduct an appraisal of avacopan for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late-August 2021 when we will write to you about how you can get involved.
These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
|
|
19 February 2021
|
In progress. Topic is in progress |
|
23 September 2020 - 21 October 2020
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual